GSK plc

GSK plc EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of GSK plc (GSK.L) as of Nov 4, 2026 is 17.11. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 28.17 — a change of -39.25% (lower).

EV/FCF

17.11

YoY

-39.25%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of GSK plc is 2025 17.11 . EV/FCF (Enterprise Value to Free Cash Flow) of GSK plc was 2024 28.17 . It decreases by -39.25% lower compared to the previous year.

The GSK plc EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
16.52 GBP
Jan 1, 2019
19.34 GBP
Jan 1, 2020
17.47 GBP
Jan 1, 2021
21.39 GBP
Jan 1, 2022
19.57 GBP
Jan 1, 2023
22.69 GBP
Jan 1, 2024
28.17 GBP
Jan 1, 2025
17.11 GBP
The GSK plc EV/FCF history
YEAREV/FCFYoY
17.11-39.25%
28.17+24.16%
22.69+15.97%
19.57-8.52%
21.39+22.45%
17.47-9.68%
19.34+17.06%
16.52-22.49%
21.32-12.65%
24.40-83.38%
146.83+394.33%
29.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

EV/FCF (Enterprise Value to Free Cash Flow) of GSK plc is 17.11 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of GSK plc changed from 28.17 to 17.11, representing a -39.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) GSK plc since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — GSK plc

All Key Metrics — GSK plc